MENU

Our Science

At Astellas Oncology, we start with promising science and empower our teams to push the boundaries of what’s possible in cancer treatment, services, and support. We call this approach “Science First,” as grounding our work in the best science helps us optimize our chances of long-term success for our patients. Our focus is on hard-to-treat cancers with few therapeutic options, which is where our impact can be greatest.

Our Products

For years, Astellas Oncology has leveraged our “Science First” approach to transform innovative science into value for patients. Oncology is our largest disease area of focus, and we are proud to have positioned ourselves as a developmental and commercial leader in that field.

Browse our list of approved products below or download our 1-pager.

Our Investigational Pipeline

We often say that our innovation is boundless, and that’s with good reason. Our current investigational pipeline represents a broad range of scientific thinking. It is designed for impact, evolving in full consideration of our patient community’s needs—and of the unmet needs within oncology communities we have yet to serve.

The safety and efficacy of these agents under investigation have not been established for the use(s) being considered. There is no guarantee that the agent will receive regulatory approval and become commercially available for the use being investigated.

Preclinical Phase I Phase II Phase III Compound
Other cancers Metastatic urothelial cancer, PD-1/PD-L1 inhibitor pretreated Metastatic urothelial cancer, previously untreated (first line) Locally advanced or metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum- containing chemotherapy pretreated Enfortumab vedotin ASG-22ME (PADCEV ) Antibody drug conjugate (ADC) directed against Nectin-4 Co-development with Seattle Genetics Non-metastatic hormone-sensitive prostate cancer Enzalutamide MDV3100 (XTANDI ® ) Androgen receptor inhibitor Collaboration with Pfizer Newly diagnosed acute myeloid leukemia with high-intensity induction of chemotherapy Newly diagnosed acute myeloid leukemia with low-intensity induction of chemotherapy Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia Post-chemotherapy maintenance acute myeloid leukemia Gilteritinib ASP2215 (XOSPATA ® ) FLT3 inhibitor Pancreatic adenocarcinoma Gastric and gastroesophageal junction adenocarcinoma Zolbetuximab IMAB362 Anti-Claudin 18.2 monoclonal antibody Multiple cancers ASP8374/PTZ-201 Anti-TIGIT antibody Multiple cancers ASP1948/PTZ-329 Anti-NRP1 antibody Multiple cancers ASP1951/PTZ-522 GITR agonistic antibody Multiple cancers ASP9801 Oncolytic virus carrying IL-7 and IL-12 Licensed from Tottori University Multiple cancers ASP7517 WT1-loaded artificial adjuvant vector cell Licensed from RIKEN Testicular cancer ASP1650 Anti-Claudin 6 monoclonal antibody Acute myeloid leukemia ASP1235/AGS62P1 Antibody-drug conjugate

Enfort umab vedotin ASG-22ME (PADCEV®)

Antibody drug conjugate (ADC) directed against Nectin-4

Co-development with Seattle Genetics

Locally advanced or metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated

Phase III

Metastatic urothelial cancer, previously untreated (first line)

Phase III

Metastatic urothelial cancer, PD-1/PD-L1 inhibitor pretreated

Phase II

Other cancers

Phase II

Gilteritinib ASP2215 (XOSPATA®)
FLT3 inhibitor

Post-chemotherapy maintenance acute myeloid leukemia

Phase III

Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia

Phase III

Newly diagnosed acute myeloid leukemia with low-intensity induction of chemotherapy

Phase III

Newly diagnosed acute myeloid leukemia with high-intensity induction of chemotherapy

Phase III

Enzalutamide MDV3100 (XTANDI®)

Androgen receptor inhibitor

Collaboration with Pfizer

Non-metastatic hormone-sensitive prostate cancer

Phase III

Zolbetuximab IMAB362
Anti-Claudin 18.2 monoclonal antibody

Gastric and gastroesophageal junction adenocarcinoma

Phase III

Pancreatic adenocarcinoma

Phase II

ASP8374/PTZ-201
Anti-TIGIT antibody

Multiple cancers

Phase I

ASP1948/PTZ-329
Anti-NRP1 antibody

Multiple cancers

Phase I

ASP1951/PTZ-522
GITR agonistic antibody

Multiple cancers

Phase I

ASP9801

Oncolytic virus carrying IL-7 and IL-12

Licensed from Tottori University

Multiple cancers

Phase I

ASP7517

WT1-loaded artificial adjuvant vector cell

Licensed from RIKEN

Multiple cancers

Phase I

ASP1650

Anti-Claudin 6 monoclonal antibody

Testicular cancer

Phase II

ASP1235/AGS62P1

Antibody-drug conjugate

Acute myeloid leukemia

Phase I

Our Trials

Our current clinical research is focused on breakthrough therapies for hard-to-treat cancers. Visit clinicaltrials.gov to learn about trials that are recruiting participants and review eligibility requirements.

Our Partnerships

We recognize that bringing the most promising new cancer medicines to patients requires collective thinking and exploration across the cancer community. Through our partnerships with renowned institutions, we bring together the brightest minds, best ideas, and most recent technology to power the promise of changing the lives of people with hard-to-treat cancers.

We build partnerships with organizations and companies that:

Drug Development & Commercialization

Pfizer | XTANDI® (enzalutamide)

Astellas and Medivation Inc., which is now a part of Pfizer, entered into a global agreement to jointly develop and commercialize enzalutamide in 2009. Astellas is currently responsible for global manufacturing, additional regulatory filings, and commercializing enzalutamide outside the United States.

Pfizer

Seattle Genetics | PADCEV™ (enfortumab vedotin-ejfv)

Seattle Genetics and Astellas are co-developing PADCEV (enfortumab vedotin-ejfv) under a collaboration that was entered into in 2007 and expanded in 2009.

Seattle genetics

Real-World Evidence

Concerto HealthAI

Astellas and Concerto HealthAI are both committed to improving outcomes for patients with acute myeloid leukemia. This partnership leverages our oncology expertise and Concerto HealthAI’s licensed, de-identified database of real-world evidence to improve understanding of responses in patients with relapse/refractory FLT3+ AML. Together, we hope to increase our understanding of these patient experiences—and work to improve them.

Concerto

Collaborations to Improve Public Health

AONN+

We are proudly collaborating with the Academy of Oncology Nurse and Patient Navigators (AONN+) to develop, standardize, and validate an evidence-based, oncology navigation-specific Acuity Tool. When finalized, this tool will empower patients with information about the level of support they need from their oncology team, as well as additional disease education, treatment options, and next steps. Altogether, our organizations hope to improve the allocation and effectiveness of navigation resources.

AONN

Pack Health

Our partnership with Pack Health aims to provide insights into the symptom experience of men with prostate cancer, both for individuals undergoing active surveillance and those receiving active treatment. Pack Health is a digital health coaching company for chronic disease management, including cancer. Pack Health helps patients increase their health outcomes, like medication adherence and overall physical health, by providing human-to-human support, accountability, and condition-specific care. Our partnership combines their platform expertise and our deep knowledge of prostate cancer into a 500-patient study of coaching in this specific population. Together, we hope to impact health outcomes through increased patient engagement and improved symptom monitoring.

Pack Health

WiserCare | Improving Patient Decision-Making

In partnership with WiserCare, a novel patient decision support platform, we are seeking to improve the experience of healthcare communications and decision-making. New approaches to the communication of risks and benefits of different treatment options are being tested via in-depth patient feedback and focus groups. The 12-month initiative aims to identify ways to reduce patient anxiety and improve both patient satisfaction and the overall care experience.

Wisercare

Astellas Oncology C3 Prize Partnerships

The C3 Prize fuels innovative ideas that go beyond treatment to holistically improve the lives of those impacted by cancer. In order to make this annual prize possible, we’ve partnered with TEDMED, HopeLab, Third Rock Ventures, and MATTER. Together, we spark new, innovative ways of caring for cancer patients.

C3

Stay Connected

Let’s stay in touch. Follow us on social media or sign up for the latest updates.

*Required field.

By submitting your information, you acknowledge that you have read and agreed to the Astellas Online Privacy Statement. You also agree to receive emails from Astellas and understand that you may opt out of Astellas subscriptions at any time.

*Required field.

By submitting your information, you acknowledge that you have read and agreed to the Astellas Online Privacy Statement . You also agree to receive emails from Astellas and understand that you may opt out of Astellas subscriptions at any time.

Thank You! We'll be in touch.